



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Toviaz™

Common Name: Fesoterodine Fumarate

PDL Category: Antispasmodics-Long Acting

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Detrol® LA	Preferred
Enablex®	Preferred
Sanctura®	Preferred
Vesicare®	Preferred

Summary

Indications and Usage: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.¹

Mechanism of Action: Presumed mechanism of action is inhibition of muscarinic receptors resulting in relaxation of the bladder's smooth muscle tissue, thus reducing the symptoms of OAB.¹

Dosage Forms: Extended Release Tablets: 4mg and 8mg

Recommended Dosage: 4 mg orally once daily. Based upon individual response and tolerability, dose may be increased to 8 mg once daily. The daily dose of Toviaz should not exceed 4 mg in the following populations: Patients with severe renal insufficiency (CLCR <30 mL/min) and patients taking potent CYP3A4 inhibitors, such as ketoconazole, itraconazole and clarithromycin.

Common Adverse Drug Reactions: Dry mouth and constipation.¹

Contraindications: Patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or severe liver impairment.¹

Manufacturer: Pfizer Labs

Analysis: Toviaz™ is a new once daily medication indicated for the treatment of OAB symptoms. In the two studies used to gain FDA approval, Toviaz™ was only compared to placebo. Although there are no head to head studies available, a post hoc analysis was done comparing Toviaz™ and Detrol® LA. Both treatments were significantly more effective than placebo for treating OAB symptoms. Toviaz™ was statistically significantly more effective than Detrol® LA for the endpoints of incontinence and severe urgency. Comparator studies are needed to determine if there is superiority of one product over another. It is recommended that Toviaz™ be added to the Preferred Drug List as a preferred drug.

IME Recommendation:

<input checked="" type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	

1. Toviaz™ [package insert]. New York, NY: Pfizer Labs; 2008.